Cdc42bpg signaling in arteriosclerosis and vascular fibrosis
Cdc42bpg signaling in arteriosclerosis and vascular fibrosis
批准号:
10448070
负责人:
DWIGHT A. TOWLER
金额:
$16.4万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-07-05 至 2024-06-30
关键词:
AllelesAmputationAngiotensin IIAnimalsAortaArteriesArteriosclerosisAtherosclerosisBindingBinding ProteinsBiological AssayBlood VesselsBone MarrowC57BL/6N MouseCardiometabolic DiseaseCardiovascular DiseasesCardiovascular systemCause of DeathCellsCholesterolChronic Kidney FailureCollagenCollagen GeneDataDiabetes MellitusDietDiseaseDistalDyslipidemiasElementsEndocrineEpitopesExonsFamilyFamily memberFibrosisFunctional disorderFutureGTP-Binding ProteinsGene ExpressionGenesGenetic TranscriptionHeart failureHybridsHyperparathyroidismHypertensionHyperuricemiaImpairmentInflammatoryInfusion proceduresKnockout MiceLengthLow Density Lipoprotein ReceptorLuciferasesMapsMediatingMedicalMedicineMessenger RNAMetabolicMetabolic syndromeMetabolismMethodsMineralsModelingMusMuscular DystrophiesMyotonic DystrophyObesityParathyroid Hormone ReceptorPathologicPhase III Clinical TrialsPhenocopyPhenotypePhosphotransferasesPhysiologyPlayPre-Clinical ModelProtein KinaseProteinsPublicationsRNA InterferenceROCK1 geneReagentReceptor SignalingRegulator GenesReporterRiskRoleSM 22 muscle proteinSignal TransductionSmall Interfering RNASmooth Muscle MyocytesStructureThromboembolismTissuesTransactivationTranscriptional ActivationTranscriptional RegulationTwo-Hybrid System TechniquesValidationVascular Smooth MuscleVascular calcificationarterial stiffnessassay developmentbaseblood pressure controlbonecalcificationcollegecoronary fibrosiscrosslinkdiabetogenicdimergraft vs host diseasein vivoinhibitorinsightinterestkidney fibrosisknock-downliquid chromatography mass spectrometrymaterial transfer agreementmembermineralizationmyocardinnovelprogramspromoterreconstitutionresponserhoscreeningskeletalsmall moleculestroke risktranscription factorwestern diet
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Cardiovascular disease is leading cause of death in the U.S. Assiduous control of blood pressure, cholesterol,
and diabetes has yielded significant but incomplete benefit by mitigating atherosclerosis & thromboembolism.
Arteriosclerotic conduit vessel stiffening, an overlapping yet distinct disease, also increases risk for stroke,
heart failure and amputation risk. No therapies currently treat arteriosclerosis, or the pathological vascular
calcification and fibrosis. We've identified that vascular smooth muscle (VSM) parathyroid hormone receptor
(PTH1R) signaling limits fibrosis, down regulating transcription driven by hybrid CT(A/T)6GG MEF/SRF
cognates in Col3a1 and Cola1 genes. PTH1R restrains mycardin-related transcription factor – a (Mkl1)
activation of these elements. We identified that muscular dystrophy protein kinase family members – including
ROCK2 & Cdc42 binding proteins (Cdc42bps) – play critical roles in supporting VSM Col3a1 gene expression
downstream of PTH1R – mediated inhibition. Cdc42bpg is particularly important - with knockdown almost
completely reversing Col3a1 induction occurring with VSM PTH1R deficiency – and is selectively upregulated
in aorta by profibrotic angiotensin II (AngII) infusion. Moreover, Cdc42bpg expression significantly stimulates
Mkl1-dependent activation of the Col3a1 promoter – the first known, context-informed assay of Cdc42bpg
bioactivity. Per Pharos only 8 publications exist on Cdc42bpg, and assays of its functions are rudimentary to
non-existent. We propose the following Tasks for this 1-year R03: Task1: Advance and refine our new
transcription-based assay of Cdc42bpg activity for systematic domain structure-function analyses. The
Cdc42bpg transcriptional regulation assay is deployed in HEK293T cells to identify Cdc42bpg domains
necessary to support Col3a1 gene expression via Mkl1. Key observations are independently confirmed in A7r5
aortic VSM. Task2: Establish the Cdc42bpg interactome as regulated by the PTH1R. Cdc42 is unlikely to
be the only, or even primary, regulator of Cdc42bpg as relevant to fibrosis. The Cdc42bpg interactome will help
identify relevant regulators, providing insights useful for detailed structure-activity refinement. Tandem liquid
chromatography – mass spectrometry will identify proteins that co-precipitate following cross-linking with
epitope-tagged Cdc42bpg & key subdomains expressed in HEK and A7r5 cells. Focus will be upon those
Cdc42bpg interactions that are regulated by PTH1R signals & modulate Col3a1 gene expression. Task3:
Study the impact of Cdc42bpg deficiency in AngII - induced cardiovascular fibrosis. The Cdc42bpg-/-
knockout mouse (C57BL/6N background) has been generated by KOMP2-BCM, & is being imported to the
Towler lab. B6N mice are very susceptible to AngII-induced fibrosis. Thus, arterial, myocardial, and renal
fibrosis in the B6N.Cdc42bpg-/- mice will be compared to control B6N animals challenged with AngII infusion in
the first in vivo assessment. Cdc42bpg-null alleles will be crossed onto the LDLR-/- background, enabling
future studies of Cdc42bpg in diet-induced atherosclerosis, diabetes, & metabolic syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Texas Southwestern - Stimulating Access to Research in Residency (UT-StARR) Program
-
批准号:10655275
-
项目类别:
-
资助金额:$33.48万
-
财政年份:2021
-
负责人:DWIGHT A. TOWLER
-
依托单位:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
-
批准号:8597586
-
项目类别:
-
资助金额:$32.84万
-
财政年份:2012
-
负责人:DWIGHT A. TOWLER
-
依托单位:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
-
批准号:8856647
-
项目类别:
-
资助金额:$39.77万
-
财政年份:2012
-
负责人:DWIGHT A. TOWLER
-
依托单位:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
-
批准号:8535817
-
项目类别:
-
资助金额:$46.41万
-
财政年份:2012
-
负责人:DWIGHT A. TOWLER
-
依托单位:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
-
批准号:8697129
-
项目类别:
-
资助金额:$47.78万
-
财政年份:2012
-
负责人:DWIGHT A. TOWLER
-
依托单位:
Endocrine Regulation of Calcific Aortic Valve Sclerosis: PTH/PTHRP Receptor Signa
-
批准号:8352879
-
项目类别:
-
资助金额:$5.16万
-
财政年份:2012
-
负责人:DWIGHT A. TOWLER
-
依托单位:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
-
批准号:7608622
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2008
-
负责人:DWIGHT A. TOWLER
-
依托单位:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
-
批准号:8020994
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2008
-
负责人:DWIGHT A. TOWLER
-
依托单位:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
-
批准号:7762246
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2008
-
负责人:DWIGHT A. TOWLER
-
依托单位:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
-
批准号:7364683
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2008
-
负责人:DWIGHT A. TOWLER
-
依托单位:
TNF-ALPHA AND BMP2-WNT SIGNALING IN DIABETIC VASCULAR DISEASE
-
批准号:8217261
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2008
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-WNT SIGNALING IN CARDIOVASCULAR CALCIFICATION
-
批准号:8477231
-
项目类别:
-
资助金额:$45.95万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-WNT SIGNALING IN CARDIOVASCULAR CALCIFICATION
-
批准号:8597587
-
项目类别:
-
资助金额:$15.14万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-Wnt Signaling in Cardiovascular Calcification
-
批准号:7258917
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-Wnt Signaling in Cardiovascular Calcification
-
批准号:7449728
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-Wnt Signaling in Cardiovascular Calcification
-
批准号:7640902
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-Wnt Signaling in Cardiovascular Calcification
-
批准号:6944594
-
项目类别:
-
资助金额:$38.25万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-Wnt Signaling in Cardiovascular Calcification
-
批准号:7125488
-
项目类别:
-
资助金额:$37.23万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-WNT SIGNALING IN CARDIOVASCULAR CALCIFICATION
-
批准号:8290230
-
项目类别:
-
资助金额:$22.48万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
MSX2-WNT SIGNALING IN CARDIOVASCULAR CALCIFICATION
-
批准号:7984957
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2005
-
负责人:DWIGHT A. TOWLER
-
依托单位:
海外基金